Latitude - Lateral Lymph Node Attitude Study
Launched by SAHLGRENSKA UNIVERSITY HOSPITAL · Mar 19, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Patients with advanced rectal cancer will receive standard care, if lateral lymph nodes exist after neoadjuvant treatment they will be operated accordingly. The focus will be to compare two groups (with and without lateral lymph node clearance) regarding function, QoL and oncologic outcome.
We will also aim to identify features on MRI to improve diagnostic ability.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older
- • written informed consent
- • adenocarcinoma verified tumour below ≤ 8 cm from anal verge measured by rectoscopy and/or MRI
- • clinical tumor (cT) stage cT3, cT4a or cT4b on MRI or
- • adenocarcinoma verified tumour at any height ≤ 15 cm from anal verge measured by rectoscopy and/or MRI regardless of T/N stage with visible lateral lymph node (according to definition 2.4.2) on pre-therapeutic MRI or PET-CT
- Exclusion Criteria:
- • Not biopsy confirmed rectal cancer (adenocarcinoma)
- • Recurrent rectal cancer
- • Age below 18
- • Participation in other trials in conflict with the protocol and end-points of the Latitude study
- • No informed consent
Trial Officials
Eva Angenete, MD PhD
Principal Investigator
Sahlgrenska Universitetssjukhuset
About Sahlgrenska University Hospital
Sahlgrenska University Hospital, a leading healthcare institution in Sweden, is at the forefront of clinical research and innovation. Affiliated with the University of Gothenburg, the hospital integrates advanced medical care with cutting-edge research, facilitating a collaborative environment for scientific exploration and clinical trials. With a commitment to improving patient outcomes, Sahlgrenska University Hospital focuses on a wide range of therapeutic areas, leveraging its multidisciplinary expertise to advance healthcare solutions. The institution is dedicated to fostering ethical research practices and ensuring the highest standards of patient safety and care in all clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gothenburg, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported